Abeona Expands ZEVASKYN Access with New York Treatment Center Activation
Summary
Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center (QTC) for ZEVASKYN, its gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion significantly broadens patient access to ZEVASKYN in the critical New York metropolitan area and across the Northeast. For a small-cap biotech company, increasing the number of QTCs is a material step in the commercialization ramp-up of an approved product, directly impacting potential revenue and market penetration. This development follows the company's recent 10-K, which highlighted the initial commercialization of ZEVASKYN. Investors will be watching for further QTC activations and updates on ZEVASKYN's sales trajectory.
At the time of this announcement, ABEO was trading at $4.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $261.3M. The 52-week trading range was $3.93 to $7.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.